This Drug is the Best and Worst News for Cystic Fibrosis

Not long ago, Vertex Pharmaceuticals scored a big one for their investors—the European Commission has approved the use of ORKAMBI® (lumacaftor/ivacaftor), for the treatment of cystic fibrosis.

This breakthrough treatment will be used to treat people (12 and older) who’ve been diagnosed with cystic fibrosis and have two copies of a mutated gene called F508del.

Are people jumping up and down?


Are mothers doing their happy dance?


You bet your Bippy they are! People who have cystic fibrosis battle each and every day just to breathe; it’s a debilitating and progressive disease, and nearly half of all sufferers don’t live beyond their mid-40s.

So while this news is pretty fantastic for cystic fibrosis patients, including those here in the United States (it’s also been approved by the FDA), the drug’s cost of nearly $710 a day is wreaking havoc, financially!

According to Vertex, they’ve spent billions and billions of research dollars bringing this drug to market, which has taken them nearly 15 years. However, the drug’s pricing for consumers is blasting away the reserves of families’ life-savings; it’s wreaking havoc on Medicaid and at what cost?!

Is there a simple solution?

How can the increasing cost of medications be stopped?!

And yet, I applaud Vertex to having the dedication and the chutzpah to develop it. It is SAVING LIVES—and that’s what’s REALLY important.

Alisha Stone

Alisha Stone

Alisha Stone has a BA in psychology and is dedicated to improving the lives of others living with chronic illnesses.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email